Tweenvest Stocks

CanBas Co., Ltd. (TSE: 4575)

Health Care · Biotechnology · JP

¥802.00

+1.39% today · -40.5% 1Y

CanBas Co., Ltd. (TSE: 4575) operates in the Biotechnology industry within the Health Care sector. The company is valued at $96.42M and employs 14 people.

Over the last twelve months the share price has lost 40.5%, trading between 506.00 and 1.56K.

Tweenvest scores CanBas Co., Ltd. across four factors: quality 36/100. Its strongest factor is quality.

4575 price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$96.42M
Revenue (TTM)
P/E
EPS
-66.39
Dividend yield
Beta (5Y)
-0.81
52-week high
¥1,558.00
52-week low
¥506.00
Avg volume (3M)
Shares outstanding
19.11M
Employees
14
Next earnings

About CanBas Co., Ltd.

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.

ISIN
JP3244570002
Founded
2000
Listed since
Sep 17, 2009
Exchange
The Tokyo Stock Exchange
Currency
JPY
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$467.44B$264.52-0.17%
Amgen Inc.NasdaqGS: AMGN$239.95B$443.84+1.03%
Gilead Sciences, Inc.NasdaqGS: GILD$181.95B$146.74+0.42%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$138.79B$547.59-0.08%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$82.73B$828.50-0.66%
argenx SEENXTBR: ARGX$63.06B864.20-4.19%
CSL LimitedASX: CSL$57.94BAU$169.11+0.48%
Moderna, Inc.NasdaqGS: MRNA$55.45B$138.89-4.26%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.